The latest news about DMG Deutsche Malaria GmbH.

April 2024:  Standby Treatment for Travellers

Non-immune travellers to Sub-Saharan Africa face profound risk from a malaria infection. DMG is developing a standby treatment to significantly enhance travel safety. MalaJic is a paradigm shifting innovative radical cure.

Malaria Day 2023:  Triple combination therapy for severe malaria

Deutsche Malaria's flagship project of developing a triple combination therapy for uncomplicated and severe Malaria is progressing to clinical trials. Deutsche Malaria is now seeking additional funding from strategic investors.

June 2022: Progress in triple combination project 

Progress in the development of Fosmidomycin-Clindamycin-Artesunate as triple combination therapy for severe malaria complicated by concomitant bacterial.

As the Company’s priority project, significant progress is being made with the preparatory work, as financed by the EU Malaria Fund, for the clinical studies that are scheduled to commence in Gabon later this year. With the prospect of a successful outcome, meeting the regulatory requirements for marketing approval in 2024, their financing is seen as an opportunity for investors.

June 2021: DMG Receives Financing from European Union Malaria Fund

Deutsche Malaria to receive financing to develop Fos-Clin-Art - a triple combination therapy for severe malaria.